Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

Association of American Physicians and Surgeons (AAPS) Responds to American Medical Association's Suppression of Independent Thought


TUCSON, Ariz., Jan. 27, 2022 /PRNewswire/ -- In an open letter to Gerald Harmon, M.D., president of the American Medical Association (AMA), the Association of American Physicians and Surgeons (AAPS) objects to the AMA's advocacy of delicensing physicians who disagree with its dogmatic views.

"Why do physicians undergo a rigorous training program that is supposed to prepare them to analyze evidence and apply it to their diverse individual patients if they cannot be trusted to use their professional judgment?" asks AAPS executive director Jane Orient, M.D.

"Without a patient-physician relationship, in which the physician pledges to prescribe 'regimen for the good of my patients according to my ability and my judgment and never do harm to anyone,' the profession of medicine is dead," she adds.

With regard to COVID-19, Pandemics Data and Response (PANDA) has presented a detailed, extensively supported critique of AMA's position. The method of science requires free and open discussion, not threats to the livelihood of physicians who disagree with the AMA, states AAPS.

The Association of American Physicians and Surgeons (AAPS) is a national organization representing physicians in all specialties since 1943. Its motto is omnia pro aegroto (everything for the patient).

SOURCE Association of American Physicians and Surgeons (AAPS)


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: